keyword
MENU ▼
Read by QxMD icon Read
search

Central retinal vein

keyword
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#1
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27911421/-analysis-of-changes-in-central-macular-thickness-based-on-optical-coherence-tomography-angiography-findings-in-retinal-vein-occlusion
#2
M V Budzinskaya, A V Shelankova, M A Mikhailova, A A Plyukhova, N M Nurieva, A V Fomin
AIM: To investigate the relationship between OCT angiography measurements and central fundus changes in patients with retinal vein occlusion (RVO). MATERIAL AND METHODS: The study enrolled 21 RVO patients aged from 55 to 86 years (69.9±2.28 years), including 8 patients with ischemic central RVO (I-CRVO; 73.6±3.4 years on average) and 13 patients with branch RVO (BRVO; 67.6±3.0 years on average). Of the latter, 8 cases were ischemic (I-BRVO) and 5 non-ischemic (NI-BRVO)...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27911131/outcomes-of-patients-initially-treated-with-intravitreal-bevacizumab-for-central-retinal-vein-occlusion-long-term-follow-up
#3
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
December 2, 2016: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/27903073/comparison-between-early-or-late-intravitreal-injection-of-dexamethasone-implant-in-branch-brvo-or-central-crvo-retinal-vein-occlusion-six-months-follow-up
#4
Fernanda Pacella, Giuseppe La Torre, Stefania Basili, Monica Autolitano, Antonella Pascarella, Tommaso Lenzi, Elena Pacella
PURPOSE: The purpose of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-month follow-up. We assessed whether an earlier treatment start (within 7 days from diagnosis) could be more beneficial than a delayed (or late) treatment start (after 7 days). MATERIALS AND METHODS: The study included 81 patients (81 eyes) affected by retinal vein occlusion...
November 30, 2016: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/27902540/macular-perivenous-retinal-whitening-and-presumed-retino-ciliary-sparing-in-a-recurrent-central-retinal-vein-occlusion-associated-with-the-antiphospholipid-syndrome-and-cryoglobulinemia
#5
Dov B Sebrow, Jesse J Jung, Jason Horowitz, Jeffrey G Odel, K Bailey Freund
PURPOSE: Macular perivenous retinal whitening results from hypoperfusion-induced ischemia of the middle retina that can occur in central retinal vein occlusion (CRVO). We describe an unusual case of recurrent CRVO with macular perivenous retinal whitening and retino-ciliary venous sparing in the setting of 2 prothrombotic diseases, antiphospholipid syndrome and Type II cryoglobulinemia. METHODS: A 50-year-old man presented with intermittent loss of vision in his right eye related to a recurrent CRVO...
November 29, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27895936/neovascular-glaucoma-a-review
#6
REVIEW
Gustavo B Rodrigues, Ricardo Y Abe, Camila Zangalli, Savio L Sodre, Flavia A Donini, Danilo C Costa, Andre Leite, Joao P Felix, Marcelo Torigoe, Alberto Diniz-Filho, Homero Gusmão de Almeida
Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The development of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovascularization process in the eye is driven by the events that alter the homeostatic balance between pro-angiogenic factors, such as the vascular endothelial growth factor and anti-angiogenic factors, such as the pigment-epithelium-derived factor...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27893623/efficacy-and-safety-of-intravitreal-conbercept-injections-in-macular-edema-secondary-to-retinal-vein-occlusion
#7
Zuhua Sun, Haiying Zhou, Bing Lin, Xuan Jiao, Yingdong Luo, Feng Zhang, Shanshan Tao, Quan Wu, Zunhong Ke, Xiaoling Liu
PURPOSE: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO). METHODS: A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27886183/fingolimod-therapeutic-mechanisms-and-ocular-adverse-effects
#8
REVIEW
P Mandal, A Gupta, W Fusi-Rubiano, P A Keane, Y Yang
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms. The therapeutic effects of fingolimod are mediated via sphingosine receptors, which are found ubiquitously in various organs, including lymphoid cells, central nervous system, cardiac myocytes, and smooth muscle cells. Fingolimod-associated macular oedema (FAME) is the most common ocular side effect but retinal haemorrhages and retinal vein occlusion can occur...
November 25, 2016: Eye
https://www.readbyqxmd.com/read/27882244/evaluation-of-peripapillary-nerve-fiber-layer-after-dexamethasone-implantation-ozurdex-in-branch-retinal-vein-occlusions
#9
Muhammed Nurullah Bulut, Yusuf Özertürk, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut
Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27878430/short-term-safety-of-dexamethasone-implant-for-treatment-of-macular-edema-due-to-retinal-vein-occlusion-in-eyes-with-glaucoma-or-treated-ocular-hypertension
#10
Sofia Theodoropoulou, Abdallah A Ellabban, Robert L Johnston, Helena Cilliers, Quresh Mohamed, Ahmed B Sallam
PURPOSE: To report the short-term safety of dexamethasone implants to treat macular edema due to retinal vein occlusion (RVO), in eyes with treated glaucoma or ocular hypertension at baseline using an as-needed re-treatment regimen. METHODS: Retrospective clinical database study from two centers using the same electronic medical record system. Extracted data included: intraocular pressure (IOP), visual acuity (VA), central 1 mm retinal thickness (CRT) by optical coherence tomography, phakic status, number of injections, glaucoma treatment, and peri-operative complications...
November 22, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27870799/choroidal-thickness-changes-after-intravitreal-dexamethasone-implant-injection-for-the-treatment-of-macular-edema-due-to-retinal-vein-occlusion
#11
Ebru Esen, Selcuk Sizmaz, Nihal Demircan
PURPOSE: To investigate changes in choroidal thickness after intravitreal injection of a dexamethasone implant for macular edema due to retinal vein occlusion. METHODS: Thirty-one eyes of 31 patients, treated with a single dose of a dexamethasone implant for retinal vein occlusion-associated macular edema, were included. Subfoveal choroidal thickness (SFCT) and central macular thickness of the affected eyes were compared with those of the normal contralateral eyes at baseline and 1, 3, and 5 months after injection...
December 2016: Retina
https://www.readbyqxmd.com/read/27865689/retinal-oximetry-during-treatment-of-retinal-vein-occlusion-by-ranibizumab-in-patients-with-high-blood-pressure-and-dyslipidemia
#12
C Keilani, A Halalchi, D Wakpi Djeugue, A Regis, S Abada
INTRODUCTION: In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab). METHODS: We retrospectively reviewed the medical records of six patients with visual acuity (VA) reduced by macular edema (ME) secondary to RVO with HBP and dyslipidemia, who underwent intravitreal anti-VEGF injection between October 2014 and February 2015 in the department of ophthalmology of François-Quesnay Hospital at Mantes-la-Jolie (France)...
November 16, 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#13
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
November 15, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27858854/prevalence-and-associated-factors-of-retinal-vein-occlusion-in-the-korean-national-health-and-nutritional-examination-survey-2008-2012-a-cross-sectional-observational-study
#14
Yong Un Shin, Heeyoon Cho, Jong Min Kim, Kunho Bae, Min Ho Kang, Jae Pil Shin, Eunwoo Nam, Se Woong Kang
Retinal vein occlusion (RVO) is the second most common retinal vascular diseases and there are only a few Asian population-based studies with small samples. Hypertension is one of a modifiable risk factor of RVO, but no recent studies have shown the relationship between RVO and hypertension control status. We aimed to investigate the prevalence of RVO and its associated factors in an adult Korean population.A nationwide population-based, cross-sectional study. We enrolled 37,982 participants from the Korea National Health and Nutrition Examination Survey who were 19 years or older and who had undergone ophthalmologic exams from 2008 through 2012...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27847638/aflibercept-in-branch-retinal-vein-occlusion-as-second-line-therapy-clinical-outcome-12%C3%A2-months-after-changing-treatment-from-bevacizumab-ranibizumab-a-pilot-study
#15
Magdalena A Wirth, Matthias D Becker, Nicole Graf, Stephan Michels
PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients (n = 10) with chronic macular edema secondary to BRVO were included in a retrospective analysis. These patients received aflibercept after an insufficient response to treatment with ranibizumab and/- or bevacizumab...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847619/central-retinal-vein-occlusion-concomitant-with-dengue-fever
#16
Punithamalar Velaitham, Nandini Vijayasingham
BACKGROUND: Dengue virus infection is on the rise and there is increasing number of ocular complications that are being reported. Most common ocular complications are macular edema, macular hemorrhages, and foveolitis. There are case reports on branch retinal vessel occlusions. Most of the ocular complications are attributed to the bleeding tendency and transudative process in dengue viral infection. This is a case report of ischemic central retinal vein occlusion (CRVO) concomitant with dengue fever...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27832655/cytokines-and-recurrence-of-macular-edema-after-intravitreal-ranibizumab-in-patients-with-branch-retinal-vein-occlusion
#17
Hidetaka Noma, Tatsuya Mimura, Kanako Yasuda, Hayate Nakagawa, Ryosuke Motohashi, Osamu Kotake, Masahiko Shimura
The aqueous humor levels of cytokines and growth/inflammatory factors were measured in 46 branch retinal vein occlusion (BRVO) patients with macular edema (ME) who were treated with intravitreal ranibizumab injection (IRI). Patients with recurrence of ME received further IRI as needed. The number of IRIs was significantly correlated with age, baseline best-corrected visual acuity, and baseline central macular thickness (CMT), as well as the baseline aqueous levels of 5 cytokines/factors (soluble vascular endothelial growth factor receptor-1, platelet-derived growth factor-AA [PDGF-AA], soluble intercellular adhesion molecule-1, interleukin-6 [IL-6], and IL-8)...
November 11, 2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27832196/stromal-cell-derived-factor-1-polymorphism-in-retinal-vein-occlusion
#18
Andrea Szigeti, Mónika Ecsedy, Miklós Schneider, Lilla Lénárt, Balázs Lesch, Zoltán Zsolt Nagy, Andrea Fekete, Zsuzsanna Récsán
BACKGROUND: Stromal cell-derived factor 1 (SDF1) has crucial role in the regulation of angiogenesis and ocular neovascularisation (NV). The purpose of this study was to evaluate the association between SDF1-3'G(801)A polymorphism and NV complications of retinal vein occlusion (RVO). METHODS: 130 patients with RVO (median age: 69.0, range 35-93 years; male/female- 58/72; 55 patients had central RVO, 75 patients had branch RVO) were enrolled in this study. In the RVO group, 40 (30...
2016: PloS One
https://www.readbyqxmd.com/read/27828907/correlation-of-microvascular-structures-on-optical-coherence-tomography-angiography-with-visual-acuity-in-retinal-vein-occlusion
#19
Joon-Won Kang, Romi Yoo, Youn Hye Jo, Hyung Chan Kim
PURPOSE: To analyze the correlation of superficial and deep capillary plexuses using optical coherence tomography (OCT) angiography with visual acuity in eyes with retinal vein occlusion (RVO). METHODS: We retrospectively reviewed the medical records of 33 patients with retinal vein occlusion (RVO; branch retinal vein occlusion in 21 patients, central retinal vein occlusion in 11 patients) and included 33 healthy subjects as a control group, who were evaluated by OCT angiography...
November 8, 2016: Retina
https://www.readbyqxmd.com/read/27826179/efficacy-of-single-bevacizumab-injection-as-adjuvant-therapy-to-laser-photocoagulation-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#20
Arief S Kartasasmita, Siska Takarai, Astriviani Switania, Sutarya Enus
BACKGROUND: Macular grid laser photocoagulation remains the standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO). One possible strategy for treating macular edema is to inhibit VEGF activity by competitive binding of VEGF with an anti-VEGF antibody, suggesting the therapy option with bevacizumab. However, multiple injections of anti-VEGF may lead to complications and high cost. PURPOSE: The aim of this study was to evaluate the improvement in visual acuity and central macular thickness after combination therapy of laser photocoagulation with single intravitreal bevacizumab injection in macular edema secondary to BRVO...
2016: Clinical Ophthalmology
keyword
keyword
53072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"